当前位置: 首页 >> 检索结果
1. Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
作者: Venkatesh Krishnan.;Stuart Y Keller.;Christine Chew.;Jonathan T Sims.;Ching-Yun Chang.;Ernst R Dow.;Robert J Benschop.;Rona Wang.;Athimalaipet V Ramanan.
来源: Lancet Rheumatol. 2025年7卷11期e799-e807页
Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
2. Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
作者: Gabriele De Marco.;Elizabeth M A Hensor.;Philip S Helliwell.;Shabina Sultan.;Sayam R Dubash.;Xabier Michelena.;Laura C Coates.;Paul Emery.;Ai Lyn Tan.;Dennis McGonagle.;Helena Marzo-Ortega.
来源: Lancet Rheumatol. 2025年7卷11期e776-e788页
The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.
3. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial.
作者: Scott D Uhlrich.;Valentina Mazzoli.;Amy Silder.;Andrea K Finlay.;Feliks Kogan.;Garry E Gold.;Scott L Delp.;Gary S Beaupre.;Julie A Kolesar.
来源: Lancet Rheumatol. 2025年7卷10期e708-e718页
Retraining individuals with medial compartment knee osteoarthritis to walk with a patient-specific change in their foot angle (ie, toe-in or toe-out angle) can reduce excessive joint loading related to disease progression. This study investigated the clinical, biomechanical, and structural efficacy of personalised foot progression angle modifications compared with sham treatment in patients with mild-to-moderate medial compartment knee osteoarthritis.
4. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial.
作者: Mark Hancock.;Anne Smith.;Peter O'Sullivan.;Robert Schütze.;J P Caneiro.;Robert Laird.;Kieran O'Sullivan.;Jan Hartvigsen.;Amity Campbell.;Deborah Wareham.;Ruth Chang.;Peter Kent.
来源: Lancet Rheumatol. 2025年7卷11期e789-e798页
Interventions for low back pain typically produce small and short-term effects. Cognitive functional therapy (CFT) has shown large effects up to 12 months, but long-term effects are unclear. We aimed to compare the long-term (3-year) effectiveness of CFT, delivered with or without movement sensor biofeedback, with usual care for patients with chronic disabling low back pain.
5. Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial.
作者: Thomas W Wainwright.;Tikki Immins.;Sharon Docherty.;Geoff Saunders.;Annie Hawton.;Elizabeth Goodwin.;Tim Rees.;Matthew Low.;Jo Samways.;Fran Webley.;Nikki Howard.;Paul H Lee.;Robert G Middleton.
来源: Lancet Rheumatol. 2025年7卷11期e764-e775页
Osteoarthritis of the hip is a leading cause of chronic disability. The cycling and education intervention (CLEAT) trial aimed to compare the clinical and cost-effectiveness of the cycling against hip pain (CHAIN) intervention, a group-based cycling and education programme, with usual physiotherapy care for patients with hip osteoarthritis referred for physiotherapy at a UK hospital.
6. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.
作者: Jacques Morel.;Emmanuelle Dernis.;Christian Roux.;Christophe Richez.;Olivier Brocq.;Bruno Fautrel.;Carine Salliot.;Olivier Vittecoq.;Xavier Mariette.;Frederic Lioté.;Slim Lassoued.;Cécile Gaujoux-Viala.;Arnaud Constantin.;Martin Soubrier.;Valérie Devauchelle-Pensec.;Vincent Goeb.;Jacques-Eric Gottenberg.;Hubert Marotte.;Anouck Rémy Moulard.;Claire Daien.;Gael Mouterde.;Cédric Lukas.;Joana Pissarra.;Helena Huguet.;Odile Launay.;Florence Galtier.;Marie Christine Picot.; .; .
来源: Lancet Rheumatol. 2025年7卷10期e675-e686页
Pneumococcal vaccination is recommended for patients with rheumatoid arthritis. Because immunosuppressant therapies for rheumatoid arthritis hinder vaccine efficacy, vaccination should be administered before initiating immunosuppressive drugs. We aimed to compare humoral responses in patients with rheumatoid arthritis receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before methotrexate initiation or simultaneously.
7. Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.
作者: Andreas Hess.;Koray Tascilar.;Hanna M Schenker.;Laura Konerth.;Verena Schönau.;Marina Sergeeva.;Silke Kreitz.;Jutta Prade.;Sandra Strobelt.;Mageshwar Selvakumar.;Arnd Kleyer.;Matthias Englbrecht.;Axel J Hueber.;Mario M Zaiss.;Eugen Feist.;Gerd R Burmester.;Reinhard E Voll.;Stephanie Finzel.;Christoph Baerwald.;Julie Rösch.;Frank Behrens.;Michaela Koehm.;Jose Antonio P da Silva.;Nemanja Damjanov.;Arnd Dörfler.;Georg Schett.;Jürgen Rech.
来源: Lancet Rheumatol. 2025年7卷8期e565-e575页
Rheumatoid arthritis is an inflammatory disease frequently treated with TNF inhibitors. Little is known about predictors of response to TNF inhibitors. Because clinical response in rheumatoid arthritis is measured by composite scores containing subjective patient-orientated domains (eg, pain and global disease perception), we hypothesised that patients with high disease representation in the CNS might respond better to TNF inhibitors than patients with less CNS disease representation.
8. Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial.
作者: Vibeke Strand.;Jerome Msihid.;Jennifer Sloane.;Michael C Nivens.;Jingdong Chao.;Angeliki Giannelou.;Stefano Fiore.;Lita Araujo.;Bhaskar Dasgupta.
来源: Lancet Rheumatol. 2025年7卷8期e544-e553页
Sarilumab is approved for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. We aimed to evaluate the effect of sarilumab on patient-reported outcomes.
9. Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Maciej Wieczorek.;Bartłomiej Kisiel.;Dorota Włodarczyk.;Piotr Leszczyński.;Iryna V Kurylchyk.;Ivan Vyshnyvetskyy.;Izabela Kierzkowska.;Piotr Pankiewicz.;Michał Kaza.;Martyna Banach.;Joanna Kogut.
来源: Lancet Rheumatol. 2025年7卷9期e629-e641页
Janus kinase (JAK) inhibitors are an effective treatment option in rheumatoid arthritis and other autoimmune diseases. However, the use of JAK inhibitors is associated with increased total cholesterol, LDL cholesterol, triglycerides, and creatinine kinase, reducing the net clinical benefit of using them. Adding Rho-associated protein kinase (ROCK) inhibition to JAK inhibition might provide cardioprotection as ROCK inhibitors have been shown to reduce vascular inflammation, improve endothelial function, and prevent cardiac remodelling in preclinical models. In this study we investigated CPL409116 (hereafter referred to as CPL'116), a novel dual JAK and ROCK inhibitor, in patients with rheumatoid arthritis with inadequate response to methotrexate, to assess dose-dependent effects on disease control, pharmacokinetics, and laboratory abnormalities among other safety events.
10. Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial.
作者: Annikka Polster.;Unni Olsen.;Lars Asphaug.;Kjetil Bergsmark.;Barbara Christensen.;Ida K Haugen.;Toril Hennig.;Merete Hermann-Eriksen.;Åshild Hove.;Trine Sjøvold.;Joe Sexton.;Anne Therese Tveter.;Ingvild Kjeken.
来源: Lancet Rheumatol. 2025年7卷8期e533-e543页
Hand osteoarthritis is a common musculoskeletal disease with a rising prevalence due to increased life expectancy. Because the disease is diagnosed on the basis of clinical examination and the first choice of treatment is non-pharmacological, it is not a high-risk condition. We aimed to assess the non-inferiority and cost-effectiveness of occupational therapist-led care for hand osteoarthritis compared with rheumatologist-led care.
11. Improving preventive health in inflammatory rheumatic diseases: a randomized controlled trial of an educational video intervention.
作者: Vanessa Bartsch.;Basel Habboub.;Kathrin Standfest.;Mathias Ausserwinkler.;Johannes Knitza.;Georg Schett.;Axel J Hueber.
来源: Rheumatology (Oxford). 2025年64卷10期5420-5427页
To evaluate the impact of an educational video on adherence to preventive health measures in patients with inflammatory rheumatic diseases.
12. Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.
作者: Vibeke Strand.;Kenneth C Kalunian.;Kai Wai Lee.;Caroline Seo.;Gabriel Abreu.;Raj Tummala.;Hussein Al-Mossawi.;Elizabeth A Duncan.;Catharina Lindholm.
来源: Lancet Rheumatol. 2025年7卷7期e485-e494页
In the TULIP-1 and TULIP-2 phase 3 trials, anifrolumab treatment was associated with clinical efficacy and clinically meaningful improvements in multiple patient-reported outcomes over 52 weeks in patients with moderate-to-severe systemic lupus erythematosus (SLE). At the end of TULIP-1 and TULIP-2 (week 52), eligible patients could reconsent to enter a 3-year long-term extension trial (TULIP-LTE). Here, we investigated changes in patient-reported outcomes during treatment with anifrolumab or placebo for up to 4 years in patients with SLE who were receiving standard therapy.
13. Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.
作者: Roberto Depascale.;Raffaele Da Mutten.;Julius Lindblom.;Nursen Cetrez.;Leonardo Palazzo.;Luca Iaccarino.;Andrea Doria.;Dionysis Nikolopoulos.;Mariele Gatto.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2025年64卷8期4650-4658页
To determine SLE endotypes according to B cell immunophenotyping and serological profile and assess endotypes' response to belimumab.
14. Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial.
作者: Ryu Watanabe.;Yoshiya Tanaka.;Tsutomu Takeuchi.;Shunsuke Okamoto.;Masanao Kyuuma.;Rumiko Matsumoto.;Yoichi Nakayama.;Masao Katsushima.;Motomu Hashimoto.
来源: Rheumatology (Oxford). 2025年64卷7期4190-4199页
Ozoralizumab (OZR) is a next-generation anti-TNF NANOBODY® compound. The primary objective was to evaluate the efficacy of OZR in patients with RA in varying RF and anti-citrullinated peptide antibody (ACPA) titres. The secondary objective was to evaluate the changes in RF and ACPA titres following OZR treatment.
15. Immunosuppressant withdrawal versus glucocorticoid withdrawal in SLE: 2-year outcomes of a noninferiority randomized controlled trial.
作者: Aishwarya Gopal.;Chengappa Kavadichanda.;Christina Mary Mariaselvam.;K T Harichandrakumar.;Molly Mary Thabah.;Vir Singh Negi.
来源: Rheumatology (Oxford). 2025年64卷7期4283-4291页
This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission.
16. Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study.
作者: Lorinda Chung.;Richard M Silver.;Virginia Steen.;Daniel E Furst.;Flavia V Castelino.;Marcin Trojanowski.;Robert Spiera.;Robyn Domsic.;Alicia Rodriguez-Pla.;Tamiko R Katsumoto.;Helene Goulaouic.;Hong Wang.;Melanie Espinasse.;Souheil El-Chemaly.;Rui Wang.
来源: Rheumatology (Oxford). 2025年64卷7期4299-4308页
To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies.
17. Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.
作者: Duvuru Geetha.;Christian Pagnoux.;Sebastian E Sattui.;Peter A Merkel.;Maria Weiner.;Juliana Draibe.;Stanislas Faguer.;Sarah Bray.;Rachel E Gurlin.;Monica Balcells-Oliver.;Annette Bruchfeld.;David R Jayne.; .
来源: Rheumatology (Oxford). 2025年64卷6期3863-3871页
To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide.
18. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
作者: Walter P Maksymowych.;Robert G W Lambert.;Rebecca J Bolce.;Natalia Bello.;Baojin Zhu.;Jeffrey R Lisse.;Mikkel Østergaard.
来源: Lancet Rheumatol. 2025年7卷5期e314-e322页
The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study.
19. Baseline synovitis-tenosynovitis is associated with remission in early rheumatoid arthritis, but discordance with disease activity is a changeable state.
作者: Rudresh R Shukla.;Richard J Wakefield.;Pauline Ho.;Ai Lyn Tan.;Paul Emery.;Darren Plant.;Maya H Buch.
来源: Rheumatology (Oxford). 2025年64卷6期3468-3477页
The objectives of this study were to investigate the association between baseline joint-complex inflammation [power Doppler-detected joint synovitis (PDUS) and/or tenosynovitis (PDTS)] and remission in treatment-naïve, new-onset RA patients and to evaluate concordance and discordance states between clinical disease activity and power Doppler US and transition between these states longitudinally.
20. Can treatment expectations or treatment itself in patients with arthralgia suspicious for progression to rheumatoid arthritis improve illness perceptions?
作者: Simonetta R G van Griethuysen.;Quirine A Dumoulin.;Elise van Mulligen.;Annette H M van der Helm-van Mil.
来源: Rheumatology (Oxford). 2025年64卷6期3444-3450页
Negative illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally stable in established RA. We hypothesized that IPs, especially in the cognitive domain, are modifiable in arthralgia at risk of RA. We aimed to study if receiving DMARD treatment, or the offer of DMARD treatment associates with more positive IPs in patients with clinically suspect arthralgia (CSA).
|